Angiotensin-II, Renal Anemia and Hyporesponsiveness to Recombinant Human Erythropoietin
نویسندگان
چکیده
منابع مشابه
Hyporesponsiveness to recombinant human erythropoietin.
The introduction of recombinant human erythropoietin (rh-Epo, epoetin) as a treatment for the anaemia of renal failure has transformed the management of this condition. Nevertheless, a significant number of patients fail to respond. There are many different possible causes of inadequate response to epoetin. Iron deficiency, whether absolute or functional, is considered to be the most important,...
متن کاملTreatment of renal anemia with recombinant human erythropoietin.
The physical performance of 12 anemic patients on renal dialysis was investigated following treatment of renal anemia with recombinant human erythropoietin (rhEPO; 40-120 U/kg, 3 times a week). Exercise intensity at a heart rate of 130 beats/min (PWC130) on a bicycle ergometer was assessed before rhEPO treatment, after reaching the target hematocrit (73 +/- 18 days), and in the maintenance phas...
متن کاملRecombinant Human Erythropoietin in Children with Solid Tumors and Chemotherapy-induced Anemia
Background: In patients undergoing chemotherapy for cancer, anemia is part of the progression of the disease. Considering the effects of anemia on quality of life of the patients, the prevention and treatment of chemotherapy-induced anemia is crucial. This study was aimed to evaluate the efficacy of recombinant human erythropoietin in reducing the need for blood transfusion in children with sol...
متن کاملRecombinant Human Erythropoietin in Cancer-Related Anemia
The clinical development of recombinant human erythropoietin (rHuEPO) has had a remarkable impact on the clinical practice of oncology. A decade ago, randomized, placebo-controlled trials in anemic cancer patients demonstrated that rHuEPO resulted in an improvement in hemoglobin and hematocrit, a reduction in transfusion requirements, and improvement in quality-of-life (QOL) end points. Based o...
متن کاملFactors influencing vascular hyporesponsiveness to angiotensin II.
Bartter's syndrome is characterized, in part, by hyporesponsiveness to the pressor effect of exogenous angiotensin II (AII). This has been attributed to volume contraction, hypokalemia, and/or increased prostaglandin (PG) levels. In order to investigate factors responsible for a diminished response to the pressor effect of AII, rats were made hypokalemic or volume contracted and hypokalemic (VC...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The International Journal of Artificial Organs
سال: 1999
ISSN: 0391-3988,1724-6040
DOI: 10.1177/039139889902201003